微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2011, Vol. 3 ›› Issue (3): 200-203.doi: 10.3969/j.issn.1674-5671.2011.03.05

• 基础研究 • 上一篇    下一篇

广西壮族非小细胞肺癌患者EGFR基因突变的研究

利基林, 林书瀚, 唐艳萍, 谭晓玉, 黎远冬, 邓伟, 欧超, 容敏华, 沈筱芸, 张力图   

  1. 广西医科大学附属肿瘤医院实验研究部
  • 出版日期:2011-09-25 发布日期:2011-10-17
  • 通讯作者: 张力图 E-mail:zhanglitu@gmail.com
  • 基金资助:

    广西回国基金资助课题（桂科回0575018）

EGFR mutations among 163 patients of non-small cell lung cancer with Guangxi Zhuang nationality

LI Ji-Lin, LIN Shu-Han, TANG Yan-Ping, TAN Xiao-Yu, LI Yuan-Dong, DENG Wei, 欧Chao , RONG Min-Hua, SHEN Xiao-Yun, ZHANG Li-Tu   

  • Online:2011-09-25 Published:2011-10-17

PDF (PC)

567

赞

被引次数

13

摘要： 目的 研究广西壮族非小细胞肺癌患者表皮生长因子受体(EGFR)基因突变的情况。方法 收集163例广西壮族非小细胞肺癌(NSCLC)组织，采用ARMS(amplification refractory mutation system，ARMS)法 PCR扩增检测EGFR基因外显子18、19、20及21的突变，进一步分析其突变与临床特征的关系，并与文献报道国内8个省、市的数据进行比较。结果 163例NSCLC中共检出73例EGFR基因突变，EGFR突变阳性率为44.8%，显著高于文献报道国内8个省市的总体水平（30.0%）（P＜0.05）。其中，外显子19和21突变各占突变总数38.4%。腺癌和腺鳞癌突变发生率占突变总数的80.8%，女性EGFR基因突变率（57.7%）显著高于男性（38.7%）（P＜0.05）。结论 广西壮族NSCLC患者EGFR基因突变率显著高于中国8个省、市的总体水平，其中以外显子19和21突变为多见。女性、腺癌和腺鳞癌患者是选用EGFR酪氨酸激酶抑制剂的优势人群。

关键词: 表皮生长因子受体, 非小细胞肺癌, 基因突变

Abstract: Objective  To investigate mutations of gene epidermal growth factor receptor (EGFR) in the patients of non-small cell lung cancer (NSCLC) who were Guangxi Zhuang nationality. Methods 163 cases of NSCLC tissue were enrolled in this study. Mutations  of EGFR exons 18，19，20 and 21 were detected by amplification refractory mutation system (ARMS). The relation between EGFR mutation and clinical characters were analyzed，and they were compared with the reported data from other eight domestic regions. Results Mutations were found in 73 cases，with an incidence of 44.8% which was significantly higher than other eight domestic regions (30.0%，P＜0.05).The mutations were mainly in exon 19 and 21，each of them accounted for 38.4% of total.Mutations in adenocarcinoma and adenosquamous carcinoma accounted for 80.8% of total.Mutation rate in female (57.7%) was significantly higher than that in male (38.7%). Conclusions  Incidence of EGFR mutation in NSCLC patient with Zhuang nationality is higher than that in other regions of China. Mutations in exons 19 and 21 are more common. Female patient，patients with adenocarcinoma or adenosquamous carcinoma may be the appropriate crowd to be treated with EGFR tyrosine kinase inhibitor.

Key words: Epidermal growth factor receptor, Non-small cell lung cancer, Gene mutation